D Muthukumar
University of Birmingham
8 Papers
16 Citations
D Muthukumar is an academic researcher from University of Birmingham. The author has contributed to research in topics: Medicine & Carboplatin. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Janet E. Brown,Kara-Louise Royle,Walter M Gregory,Christy Ralph,Anthony Maraveyas,O.S. Din,Tim Eisen,Paul Nathan,Thomas Powles,Richard Griffiths,Robert Jones,Naveen S. Vasudev,Matthew Wheater,A. Hamid,T. Waddell,Rhona McMenemin,Poulam M. Patel,James Larkin,Guy Faust,Jayne Swain,Janine C Bestall,Christopher McCabe,David M. Meads,Vicky Goh,Tze Min Wah,Julia Brown,Jenny Hewison,Peter Selby,Fiona Collinson,Judith E. Carser,Gopalakrishnan Srinivasan,Fiona Thistlewaite,Ashraf Azzabi,Mark Beresford,David Farrugia,Marios P. Decatris,Carys Thomas,Joanna Gale,J. J. McAleer,A. Clayton,Ekaterini Boleti,T. Geldart,Santhanam Sundar,Jason F. Lester,Nachi Palaniappan,Mohan Hingorani,Khaliqur Rehman,Mohammad Emrul Hasan Khan,Naveed Sarwar,Janine Graham,Alastair M. Thomson,Narayanan Srihari,D. Sheehan,Rajaguru Srinivasan,O. Khan,Andrew Stockdale Jane Worlding,Stergios Boussios,N Stuart,Carey F MacDonald-Smith,F. Danwata,Duncan McLaren,Aravindhan Sundaramurthy,Anna Lydon,Sharon Beesley,Kathryn Lees,Mohini Varughese,Emma Gray,Angela Scott,Mark Baxter,Anna Mullard,Pasquale F. Innominato,Gaurav Kapur,Ashok Kumar,Natalie Charnley,C. Manetta,Prabir Chakraborti,Prantik Das,Sarah Rudman,H. Taylor,Christos Mikropoulos,Martin Highley,D Muthukumar,Anjali Zarkar,Roy Vergis,Seshadri Sriprasad,P. Brulinski,Amanda Clarke,R.D. Osbourne,Melanie Harvey,Renata Dega,G. Sparrow,Urmila Barthakur,E. Beaumont,Agnieszka Michael,Emilio Porfiri,Faisal Azam,Ravi Kodavtiganti +96 more
TL;DR: In this article , the authors compared a drug-free interval strategy with a conventional continuation strategy for first-line treatment of advanced clear cell renal cell carcinoma (CRC) patients.
37
Docking Studies of Some Novel Hetrocyclic Compound as Acat Inhibitors: A Meta Analysis
TL;DR: Molecular modelling and pharmacological testing are used to identify TCM compounds that may suppress SQS activity and to explore other potential anti-hyperlipidemia targets in HepG2 cells and establish whether or not the lipid-lowering effect was due to SQS inhibition.
30
Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial
D. R. Ferry,Lucinda Billingham,Hugh Jarrett,D. Dunlop,Penella J. Woll,Marianne Nicolson,R. Shah,Joyce Thompson,James Spicer,D Muthukumar,Geraldine Skailes,Pauline Leonard,A.D. Chetiyawardana,Paula Wells,Conrad R. Lewanski,B. Crosse,Michelle Hill,Piers Gaunt,Kenneth J. O'Byrne +18 more
TL;DR: In this paper, the authors investigated the importance of the choice of platinum agent and dose of cisplatin in relation to patient outcomes and found that the lower dose of 50 mg/m2 has worse survival which is not compensated by better quality of life.
11
Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial.
R. Huddart,Sajia Hafeez,Alhadeedi Omar,Roberto Alonzi,Alison Birtle,K. C. Cheung,Ananya Choudhury,F. Foroud,Helen Gribble,Anne Rose Henry,Serena Hilman,Benjamin R Hindson,Rebecca Lewis,D Muthukumar,Duncan McLaren,Helen McNair,A. Nikapota,A. Olorunfemi,Omni Parikh,Lara H Philipps,Yvonne Rimmer,Isabel Syndikus,Angelica L. Tolentino,M. Varughese,Catalina Vassallo-Bonner,Amanda Webster,Clare Griffin,E. Hall +27 more
TL;DR: In this article , the authors report exploratory analyses of acute toxicity by concomitant therapy-fractionation schedule combination for muscle-invasive urothelial carcinoma patients.
9
LBA53 A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers.
Peter Schmid,Fiona H Blackhall,D Muthukumar,Jason F. Lester,Sajid A. Khan,J Adams,Marianne Illsley,C Macgregor,W Owadally,S-J Sarker,L Smith,Aaron Prendergast,Charlotte Ackerman,Kelly Mousa,L. Lim Farah +14 more
3